Canada's Voice For
Biotechnology
Members
| Location: |
Toronto, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.cvca.ca |
| Contact: |
Peter van der Velden (cvca@cvca.ca)
1 416 487 0519
|
| Description: |
The CVCA – Canada’s Venture Capital & Private Equity Association represents the majority of private equity companies in Canada, with over 1900 members. CVCA fosters professional development, networking, communication, research and education within the venture capital and private equity sector and represents the industry in public policy matters. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.cihr-irsc.gc.ca |
| Contact: |
Alain Beaudet (info@cihr-irsc.gc.ca)
1 613 941 2672
|
| Description: |
The Canadian Institutes of Health Research (CIHR) is the Government of Canada's agency responsible for funding health research in Canada. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.cdnseed.org |
| Contact: |
Patty Townsen (csta@cdnseed.org)
1 613 829 9527
|
| Description: |
The Canadian Seed Trade Association (CSTA) is a voluntary association composed of approximately 130 seed companies from across Canada. The seed products come from about 50 principal crops, including: grains and oilseeds, special crops, forage and turf grasses, flowers, vegetables, fruits. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Biotechnology / R&D Services |
| Website: |
www.caprion.com |
| Contact: |
Martin LeBlanc (info@caprion.com)
1 514 3603600
|
| Description: |
Caprion Proteomics is the leading provider of proteomics based services to the pharmaceutical industry. Caprion's leading proteomics discovery technology - CellCarta® - enables the discovery of novel targets for therapeutics development as well as the identification, verification, validation, along with rapid custom multiplex assay development (with technology alternative to ELISA dev.) of protein biomarkers that can significantly reduce risk and enhance productivity and decision making in pharmaceutical research and clinical development. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.cardiome.com |
| Contact: |
William Hunter (bus-dev@cardiome.com)
1 604 677 6905
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): COM.TO |
| Description: |
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESSTM(vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. |
| Location: |
Edmonton, Alberta |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.ceapro.com |
| Contact: |
Branko Jankovic (bjankovic@ceapro.com)
1 780 4214555
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): CZO.V |
| Description: |
Ceapro develops and commercializes active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. Curent R&D focus includes food/nutrition and pharma applications for these ingredients |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.celatorpharma.com |
| Contact: |
David S. Wood (dwood@celatorpharma.com)
1 604 7085858
|
| Ownership: |
Subsidiary - : |
| Description: |
Celator® is a privately held biopharmaceutical company working to develop new and more effective combination therapies to treat cancer. |
| Location: |
Oakville, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.celgene.com |
| Contact: |
Robert J. Hugin (ir@celgene.com)
1 289 2910200
|
| Ownership: |
Subsidiary - : |
| Description: |
Celgene aims to help patients live a better life by providing them with high quality therapeuticals in the field of oncology. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.ccrm.ca |
| Contact: |
Michael May (michael.may@ccrm.ca)
1 416 9783751
|
| Description: |
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and bioengineers have come together to form the Centre for Commercialization of Regenerative Medicine (CCRM). CCRM’s mission is to create and sustain a global nexus for Regenerative Medicine (RM) commercialization by unifying dynamic business leadership with high value innovative translational technology platforms based on demonstrated excellence in fundamental stem cell and biomaterial science. |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.cdrd.ca |
| Contact: |
Karimah Es Coleman (info@cdrd.ca)
1 604 8271200
|
| Description: |
CDRD is a not-for-profit research centre that transforms discoveries stemming from publicly-funded health research into viable investment opportunities for the private sector thereby bridging the commercialization gap between academia and industry. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.ceprocq.com/ |
| Contact: |
Bruno Ponsard (bponsard@cmaisonneuve.qc.ca)
1 514 2554444
|
| Description: |
The CEPROCQ is a technology transfer centre working within the Petrochemical and Chemical Institute (PCI) of Montreal. |
| Location: |
Halifax, |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.cpintercept.com |
| Contact: |
Bruce E. Holbein (bholbein@cpintercept.com)
|
| Description: |
The Chelation Partners CP Technology constitutes a new platform of chemically synthesized chelating compounds that possess anti-microbial activities that are functionally different from the various classes of known conventional anti-infectives. The new compounds have defined physical and chemical characteristics and have iron chelating capabilities of high specificity and efficiency. All pathogenic and spoilage microorganisms, whether bacterial or fungal, require a continuous iron supply for essential metabolic and defence functions. Intercepting iron through the CP Technology reduces growth of pathogens, diminishes their ability to resist other agents such as antibiotics and denial of a source of iron ultimately causes microbial death. The CP Technology offers the following types of applications INTERCEPT TM Remove Iron (Fe) from various products; Fe removal restricts microbial growth and enhances preservatives Fe removal improves product oxidative chemical stability and microbial security RESTORE TM Sequester iron in situ restricting microbial growth ; Selective Fe sequestration enhances conventional antibiotics Restores sensitivity to antibiotic resistant strains |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.toronto.ca |
| Contact: |
Matt Buist (mbuist@toronto.ca)
1 416 3923380
|
| Ownership: |
Public - : |
| Description: |
Toronto is the largest city in Canada, and is also the location of the country's largest biotech cluster. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.clera.com |
| Contact: |
(bob@clera.com)
1 647 5478947
|
| Description: |
Clera is a world leading private drug discovery and development company creating better medicines for aging related mental illnesses. |
| Location: |
Quebec, Quebec |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.co2solutions.com/ |
| Contact: |
Glenn Kelly (info@co2solutions.com)
1 418 8423456
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): CST.V |
| Description: |
CO2 Solutions is an innovator in the field of enzyme-enabled carbon capture and has been actively working to develop and commercialize the technology for power plants and other large stationary sources of carbon pollution. In the process, CO2 Solutions has built an extensive patent portfolio covering the use of carbonic anhydrase, or analogues thereof, for the efficient post‐combustion capture of carbon dioxide with low‐energy aqueous solvents. |
| Location: |
Laval, Quebec |
| Industry Sector: |
Biotechnology / R&D Services |
| Website: |
www.corealispharma.com |
| Contact: |
Yves Roy (info@corealispharma.com)
1 450 9737505
|
| Description: |
COREALIS Pharma is dedicated to the research and development of pharmaceutical finished solid dosage forms through the use of robust and innovative formulation and process technologies in order to surpass the specific needs of the pharmaceutical industry. Corealis provides formulation and process development services as well as phase I and II Clinical Trial Material manufacturing of oral dosage forms (tablet, capsule or granule) to the pharmaceutical and biotech companies. |
| Location: |
London, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.criticaloutcome.com |
| Contact: |
Wayne Danter
1 519 8585157
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): V.COT |
| Description: |
COTI is a leading-edge biotechnology firm specialized in assisting pharmaceutical, biotechnology and therapeutic companies with the accelerated discovery of small molecules to enable new drugs to be brought to market in a more timely, cost effective and efficient manner. COTI’S proprietary technology CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective. COTI is located in London, Ontario and is publicly traded on the TSX Venture Exchange under the symbol ‘COT’. For more information, visit www.criticaloutcome.com COTI’s current lead candidate is COTI-2, a novel allosteric inhibitor of AKT2, being developed for the treatment of a number of hard to treat cancers including endometrial, ovarian and pancreatic cancers. COTI is in the process of finalizing the oral formulation of COTI-2. Subsequent to this we will begin IND enabling research for the first-in-man multicentre Phase 1 Clinical Trial. Concurrently, COTI is looking for a licensing partner for COTI-2. |
| Location: |
Saskatoon, Saskatchewan |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
agbio.usask.ca/crop-development-centre |
| Contact: |
Kofi Agblor (kofi.agblor@usask.ca)
1 306 9665855
|
| Description: |
The Crop Development Centre (CDC) is a field crop research organization within the Department of Plant Sciences at the University of Saskatchewan. CDC scientists integrate basic research with genetic improvement of spring wheat, durum, canaryseed, barley, oat, flax, field pea, lentil, chickpea, fababean and dry bean. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Investor |
| Website: |
www.ctisciences.com |
| Contact: |
Ken Pastor (kpastor@ctisciences.com)
1 514 7871662
|
| Description: |
CTI Life Sciences Fund L.P. is a limited partnership formed in 2006. The Fund make venture capital investments in high quality emerging life sciences companies at the start-up and clinical development stage primarily in Canada. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.cynapsus.ca |
| Contact: |
Anthony Giovinazzo (ajg@cynapsus.ca)
1 416 7032449
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): CTH.V |
| Description: |
Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease. the Company's lead product APL-130277 is a reformulation of an approved Parkinson’s drug. |
